Dr. Marc A. Simon, MD
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
- Medicare participating
At a glance
- Medical school
- University of Maryland School of Medicine (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 151
Licensed in California since 2021, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: University of Maryland School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
CA license C171930 (first issued 2021; current) · PA license MD420221 -
Cardiovascular Disease Physician
CA license C171930 (first issued 2021; current) · PA license MD420221 -
Specialist
PA license MD420221
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- UCSF Medical Center San Francisco, CA
- UCSF Health St. Mary's Hospital San Francisco, CA
Medical groups
- University of California San Francisco (1,839 clinicians)
- UCSF Medical Group Business Services (1,598 clinicians)
- Regents of the University of California (732 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 151
- Services billed
- 1,009
- Patients’ average age
- 65
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 154 | 38 |
| Established patient office or other outpatient visit, 40-54 minutes | 77 | 59 |
| Critical care, first 30-74 minutes | 31 | 14 |
| New patient office or other outpatient visit, 60-74 minutes | 28 | 28 |
| Established patient office or other outpatient visit, 30-39 minutes | 24 | 23 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 14 | 11 |
| Insertion of tube in right heart chambers for measurement | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Uptravi (selexipag) | 53 |
| Jardiance (empagliflozin) Other prescribers in San Francisco, CA | 44 |
| Tyvaso Dpi (treprostinil) | 42 |
| Spironolactone Other prescribers in San Francisco, CA | 41 |
| Opsumit (macitentan) | 34 |
| Tadalafil | 28 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in San Francisco, CA | 18 |
| Praluent Pen (alirocumab) Other prescribers in San Francisco, CA | 15 |
| Adempas (riociguat) | 14 |
| Metoprolol Succinate Other prescribers in San Francisco, CA | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 48 payments worth $23,894 in total to this clinician.
| Merck Sharp & Dohme LLC | $16,248 |
|---|---|
| Actelion Pharmaceuticals US, Inc. | $5,455 |
| Chiesi USA, Inc. | $960 |
| United Therapeutics Corporation | $757 |
| Kerecis Limited | $197 |
| Bayer HealthCare Pharmaceuticals Inc. | $127 |
| Liquidia Technologies, Inc. | $87.23 |
| Sandoz Inc. | $49.03 |
| Consulting Fee | $18,630 |
|---|---|
| Travel and Lodging | $2,655 |
| Food and Beverage | $2,609 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Dec 8, 2025 | Consulting Fee | $7,680 |
| Merck Sharp & Dohme LLC Jun 9, 2025 | Consulting Fee | $5,760 |
| Actelion Pharmaceuticals US, Inc. Oct 24, 2025 | Consulting Fee OPSYNVI · Pulmonary Hypertension | $5,190 |
| Chiesi USA, Inc. Dec 3, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $513 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $467 |
| Chiesi USA, Inc. Dec 3, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $337 |
| Merck Sharp & Dohme LLC May 29, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Denver, CO · in-kind | $295 |
| Merck Sharp & Dohme LLC Nov 14, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $256 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $256 |
| Merck Sharp & Dohme LLC May 29, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Denver, CO · in-kind | $231 |
All 12 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Dec 8, 2025 | Consulting Fee | $7,680 |
| Merck Sharp & Dohme LLC Dec 8, 2025 | Travel and Lodging travel to Dallas, TX | $150 |
| Chiesi USA, Inc. Dec 3, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $513 |
| Chiesi USA, Inc. Dec 3, 2025 | Travel and Lodging travel to BOSTON, MA · in-kind | $337 |
| Merck Sharp & Dohme LLC Nov 14, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $256 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $467 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Plano, TX · in-kind | $256 |
| Actelion Pharmaceuticals US, Inc. Oct 24, 2025 | Consulting Fee OPSYNVI · Pulmonary Hypertension | $5,190 |
| Merck Sharp & Dohme LLC Jun 9, 2025 | Consulting Fee | $5,760 |
| Merck Sharp & Dohme LLC Jun 9, 2025 | Travel and Lodging travel to Denver, CO | $150 |
| Merck Sharp & Dohme LLC May 29, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Denver, CO · in-kind | $295 |
| Merck Sharp & Dohme LLC May 29, 2025 | Travel and Lodging WINREVAIR · CARDIOVASCULAR · travel to Denver, CO · in-kind | $231 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $25,854 in research payments for these studies, mostly to the institutions running them.
- A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
United Therapeutics Corporation · Active, not recruiting · NCT05203510
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.